Xu, Binghe http://orcid.org/0000-0003-4195-337X
Li, Wei
Zhang, Qingyuan
Li, Qiao
Wang, Xiaojia
Li, Huiping
Sun, Tao
Yin, Yongmei
Zheng, Hong
Feng, Jifeng
Zhu, Huaqi
Siddiqui, Asna
Macharia, Harrison
Knott, Adam
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 28 June 2022
Accepted: 13 October 2022
First Online: 4 December 2022
Declarations
:
: BX reports institutional research funding (investigator fees for this study to his institution) from F. Hoffmann-La Roche Ltd; and consultant/advisory roles for Novartis, Roche, and AstraZeneca. WL, QZ, QL, XW, HL, TS, YY, HZhe, and JF all report institutional research funding (investigator fees for this study) from F. Hoffmann-La Roche Ltd. HZhu and HM are employees of F. Hoffmann-La Roche Ltd. AS is an employee of Roche Products Limited. AK is an employee of Roche Products Limited and holds stock in F. Hoffmann-La Roche Ltd. All authors received research funding in the form of third-party writing assistance for this manuscript, provided by F. Hoffmann-La Roche Ltd.
: This study was conducted in full conformance with the International Council for Harmonisation (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or with the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. The protocol, the informed consent forms, and any accompanying material provided to patients were submitted to the independent ethics committee (IEC) by the Principal Investigator and reviewed and approved before the study was initiated. A full list of the IECs at participating institutions is provided with the primary analysis [CitationRef removed].
: Written informed consent for participation in the study had to be obtained before performing any study-specific screening tests or evaluations. Informed consent forms for enrolled patients and for patients who were not subsequently enrolled were maintained at the study site.
: Not applicable.